Top Markets
#1 龙虾 (Lobster) 龙虾 (Lobster) +36.79%
#2 Cortex Cortex +32.68%
#3 DexNet DexNet +23.20%
#4 wojak wojak +21.54%
#5 Akedo Akedo +20.63%
#6 Pons Pons +14.34%
#7 APEX APEX +13.93%
#8 OpenEden OpenEden +12.38%
#9 TDCCP TDCCP +11.04%
#10 Quack AI Quack AI +9.77%
Coin of the day
龙虾 (Lobster) 龙虾 (Lobster)
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Pharma Mar, S.A. Pharma Mar, S.A.

Pharma Mar, S.A.

PHM
Rangering i aksjer #7111
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and... Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
Aksjekurs
$99.34
Markedsverdi
$1.72B
Endring (1 dag)
0.18%
Endring (1 år)
2.70%
Land
ES
Handel Pharma Mar, S.A. (PHM)

Kategori

Healthcare
Inntekter for Pharma Mar, S.A. (PHM)
Inntekter i 2026 TTM: 0
Ifølge Pharma Mar, S.A. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Pharma Mar, S.A. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH